| Dear Voornaam,
FLASH, or ultra-high dose rate radiotherapy, is attracting major interest for its potential to improve treatment for patients while suppressing tumour growth.
Our RadNet community is hosting an online workshop to introduce the FLASH infrastructure they developed to bring together the communitys multidisciplinary skills and capabilities to enable cutting edge research in this new and exciting area.
Join the workshop from 11am-2pm on 30 November to hear Karen Kirby, David Fernandez Antoran, Kristoffer Petersson and colleagues discuss the latest FLASH research and how you can get involved. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
APPLY TO OUR PREVENTION AND POPULATION RESEARCH PROJECT AWARDS If your research is focusing on answering key questions in prevention and population research including behavioural and lifestyle interventions, epidemiology and risk stratification, you can apply to our Prevention and Population Research Project Awards to get a chance to receive up to 500k in funding.
Dont hesitate to get in touch with our office before you begin an application. We will advise you confidentially on your eligibility and check your proposal is within remit.
Applications are open until 14 December. Learn more about eligibility and apply today.
|
|
|---|
|
|---|
|
|
 WHY OUR BODIES FIGHT FLU BETTER THAN CANCER Scientists at the Cancer Research UK Scotland Institute have uncovered the parts of the immune system which often prevent it recognising cancer as a threat, but which allow it to perceive the danger posed by flu.
Pirello et al used fluorescently labelled strains of influenza and a modified melanoma model to track antigen from the tissues to the lymph nodes.
Their findings, published in Science Immunology, showed that while the immune system reacted vigorously to the flu virus, it did not fully activate against cancer.
Specifically, they found that tissue and lymph node dendritic cell activation is driven by cotransfer of contextual cues. In tumours, incomplete dendritic cell activation in the tumour microenvironment is mirrored by lymph noderesident dendritic cells. Whereas during influenza infection, dendritic cells cotransferred viral antigen along with pathogen-associated molecular patterns in the form of TLR ligands, which directly promoted lymph noderesident dendritic cell activation through MyD88 signalling. |
|
|---|
|  CONVERGENCE SCIENCE CENTRE SYMPOSIUM: WHEN ENGINEERING MEETS CANCER RESEARCH Mehmet Toner from Harvard Medical School and Massachusetts General Hospital will give the keynote speech at our Convergence Science Centres upcoming symposium on 17 January 2024.
Toner will speak about his work in biomedical sciences spanning bio-sensing, regenerative medicine, and tissue engineering.
The symposium will highlight innovation at the interface of biological and physical sciences. It will take place at the Royal Geographical Society in London. |
|
|---|
|
|---|
|
|
OPEN NEXT JANUARY: 9M FUNDING CALL UNITES DISCIPLINES FOR IMMUNO-ONCOLOGY David Crosby, our head of prevention and early detection research has been shaping a major research initiative on immuno-oncology with the Office for Life Sciences (OLS).
The OLS and the Medical Research Council will launch a call for consortia proposals to establish a Cancer Immunotherapy Response Research Platform next year.
David discusses how you can get involved in the four-year award, which will offer up to 9m to develop the platform, and how its intended to accelerate our scientific understanding of immuno-oncology into therapeutic options for the clinic. |
|
|---|
|
|---|
|
|
 BUILD YOUR DATA-DRIVEN OR MEDTECH CONCEPT WITH OUR ENTREPRENEURIAL PROGRAMME Our Cancer Tech Accelerator is now inviting applications for its third year after two successful cohorts. This initiative aims to propel cancer researchers and their early-stage technologies, leveraging data, AI, or MedTech to advance cancer detection, diagnosis, monitoring, or treatment.
Whether your idea is just budding or you're actively developing a project, join our five-day bootcamp and secure direct funding to bring your vision to life. With support from Cancer Research Horizons, Roche, Blood Cancer UK, The Brain Tumour Charity and Capital Enterprise you'll be sure to forge valuable industry connections.
Curious to learn more? The Cancer Tech Accelerator team is ready for a confidential chat about your project's potential fit for the accelerator. The application deadline is 16 February, 2024. |
|
|---|
|  RICHARD KENNEDY TO REFLECT ON BIOMARKER DEVELOPMENT Richard Kennedy, Global VP and Medical Director of Almac Diagnostic Services will be the special guest for the Manchester Cancer Research Centre Directors Lecture on 17 November.
Richard will speak on Lessons learnt in 20 years of Biomarker Development, covering topics from considerations in the pre-clinical phase, analytical validation and clinical validation to challenges for the future.
|
|
|---|
|
|---|
|
|
| | | London, UK 21 November 2023 |
|
|---|
|
|---|
| | | London, UK 29 November 2023 |
|
|---|
|
|---|
| | | London, UK 17 January 2024 |
|
|---|
|
|---|
| | | Manchester, UK 27 February 2024 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
